Another generic from Dr. Reddy's
The generics drugmaker plans to tackle AstraZeneca's blockbuster antipsychotic drug Seroquel next.
Late last month, the U.S. Food and Drug Administration had approved Dr. Reddy's abbreviated new drug application for the generic drug. Seroquel is approved for the treatment of schizophrenia and bipolar mania.
According to IMS Health, U.S. sales of the Seroquel brand amounted to about $4.6 billion for the 12 months ended December 31, 2011.
Last month, Dr. Reddy's launched its generic version of Pfizer Inc.'s (PFE) antipsychotic drug, Geodon (ziprasidone) in the U.S. The drug is approved for the treatment of schizophrenia and bipolar disorder.
We expect generic launches at regular intervals to add to Dr. Reddy's Global Generic revenues, which soared 57% year-over-year to $402 million in the third quarter of fiscal 2012.
During the reported quarter, generics' revenues climbed 133% in North America, 15% in Russia and other CIS (Commonwealth of Independent States) markets, 14% in Europe and 11% in India. Growth was mainly driven by the launch of a generic version of Eli Lilly & Co.'s (LLY) Zyprexa (olanzapine) 20 mg.
We currently have a "neutral" recommendation on Dr. Reddy's. The stock carries a Zacks #2 Rank ("buy" rating) in the short-run. We believe Dr. Reddy's is in a strong position to benefit from the huge potential presented by the U.S. generics market, as quite a few blockbuster drugs such as Johnson & Johnson's (JNJ) Concerta and Pfizer's Lipitor have lost patent exclusivity, and more drugs are slated to go off-patent in the coming years.
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The market's cheap money addiction is laid bare. No one knows how it will end.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.